About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Sponsored by

Translational Lung Cancer Research is sponsored by Nanjing General Hospital of Nanjing Military Command, Nanjing, China

Sponsored by

Review Article

The epidemiology of lung cancer
Patricia M. de Groot, Carol C. Wu, Brett W. Carter, Reginald F. Munden
Lung cancer screening with low-dose CT: a world-wide view
Paul F. Pinsky
Selecting lung cancer screenees using risk prediction models—where do we go from here
Martin C. Tammemägi
Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs
Lisa M. Lowenstein, Gary M. R. Deyter, Shawn Nishi, Tianhao Wang, Robert J. Volk
The importance of incorporating smoking cessation into lung cancer screening
Jennifer Anne Minnix, Maher Karam-Hage, Janice A. Blalock, Paul M. Cinciripini
Appropriate screening intervals in low-dose CT lung cancer screening
Marjolein A. Heuvelmans, Matthijs Oudkerk
Lung cancer screening: nodule identification and characterization
Ioannis Vlahos, Konstantinos Stefanidis, Sarah Sheard, Arjun Nair, Charles Sayer, Joanne Moser
Lung cancer prediction using machine learning and advanced imaging techniques
Timor Kadir, Fergus Gleeson
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
Blood based biomarkers beyond genomics for lung cancer screening
Samir M. Hanash, Edwin Justin Ostrin, Johannes F. Fahrmann

Review Article

Chronic obstructive pulmonary disease (COPD) and lung cancer screening
Robert P. Young, Raewyn J. Hopkins
Coronary artery calcification in lung cancer screening
James G. Ravenel, John W. Nance
Extrapulmonary neoplasms in lung cancer screening
Myrna C. B. Godoy, Charles S. White, Jeremy J. Erasmus, Carol C. Wu, Mylene T. Truong, Reginald F. Munden, Caroline Chiles

Original Article

The 180 splice variant of NCAM—containing exon 18—is specifically expressed in small cell lung cancer cells
Ann Vander Borght, Mieke Duysinx, Jos L. V. Broers, Monique Ummelen, Frank W. Falkenberg, Christine Hahnel, Bernard A. M. van der Zeijst
The prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis
Jianrong Zhang, Jieyu Wu, Qihua He, Wenhua Liang, Jianxing He
The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer
Hengrui Liang, Zhenkui Pan, Xiuyu Cai, Wei Wang, Chengye Guo, Jiaxi He, Yuehan Chen, Zhichao Liu, Bo Wang, Jianxing He, Wenhua Liang, on behalf of AME Lung Cancer Cooperative Group
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience
Mª Carmen Areses Manrique, Joaquín Mosquera Martínez, Jorge García González, Francisco Javier Afonso Afonso, Martín Lázaro Quintela, Natalia Fernández Núñez, Cristina Azpitarte Raposeiras, Margarita Amenedo Gancedo, Lucía Santomé Couto, Mª Rosario García Campelo, Jose Muñoz Iglesias, Alexandra Cortegoso Mosquera, Rocío Vilchez Simo, Joaquín Casal Rubio, Begoña Campos Balea, Iria Carou Frieiro, Guillermo Alonso-Jaudenes Curbera, Urbano Anido Herranz, Jesus García Mata, José Luis Fírvida Pérez
Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer
Federico Rotolo, Chang-Qi Zhu, Elisabeth Brambilla, Stephen L. Graziano, Ken Olaussen, Thierry Le-Chevalier, Jean-Pierre Pignon, Robert Kratzke, Jean-Charles Soria, Frances A. Shepherd, Lesley Seymour, Stefan Michiels, Ming-Sound Tsao, on behalf of the LACE-Bio Consortium

Guideline

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel
Yi-Long Wu, Chang-Li Wang, Mei-Lin Liao, Zhong-Zhen Guan, Chen-Yan Gao, Shun Lu, Ming- Fang Zhao, Jie Wang, Xiao-Qing Liu, Jin-Ji Yang, Jun Liang, Wei-Min Mao, Bao-Hui Han, Xu- Chao Zhang, Yong Song, Ji-Feng Feng, Sheng-Lin Ma, Gang Wu, Cai-Cun Zhou, Ke-Neng Chen, Ying Cheng, Yong He, Chun Chen, Qun Wang, Ji-Zhen Lin, Bo Zhu, Yun-Peng Liu, Yi Hu, Gui-Bin Qiao, Qing Zhou, Qi-Bin Song, Nan Wu, Lin Wu, Cheng Huang, Xiao-Long Fu, Jian-Ping Xiong, Jie Hu, Cheng-Ping Hu, Jian-Hua Chang, Qiong Zhao, Jun Zhao, Peng- Hui Zhou, Zhi-Yong Ma, Yuan Chen, He-Long Zhang, Fan Yang, Jian-Jun Wang, Yue-Yin Pan, Xue-Ning Yang, Yun Fan, Zhe Liu, Wen Fan, Nong Yang, Yan-Fang Guan, Hao Sun, Wen-Zhao Zhong

Maintenance Therapy

Maintenance therapy in non-small cell lung cancer
Gerald Schmid-Bindert

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?
Yoshihisa Kobayashi, Tetsuya Mitsudomi
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach
Javier de Castro Carpeño, Cristóbal Belda-Iniesta
Irreversible EGFR-TKIs: dreaming perfection
Lorenza Landi, Federico Cappuzzo
Angiogenesis in cancer: anti-VEGF escape mechanisms
Gerald W. Prager, Marina Poettler, Matthias Unseld, Christoph C. Zielinski
MET inhibition in lung cancer
Jessica Menis, Matteo Giaj Levra, Silvia Novello
Activated RET and ROS: two new driver mutations in lung adenocarcinoma
Marc Bos, Masyar Gardizi, Hans-Ulrich Schildhaus, Reinhard Buettner, Juergen Wolf
Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Lothar R Pilz, Christian Manegold, Gerald Schmid-Bindert
Potential toxicities of prophylactic cranial irradiation
Frank A. Giordano, Grit Welzel, Yasser Abo-Madyan, Frederik Wenz
ALK and ROS1 as a joint target for the treatment of lung cancer: a review
Raimon Puig de la Bellacasa, Niki Karachaliou, Roger Estrada-Tejedor, Jordi Teixidó, Carlota Costa, José I. Borrell
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches
Ana Christina Garrido-Castro, Enriqueta Felip
From tissue to molecular phenotyping: Pre-analytical requirements
Thomas R. Muley, Felix JF. Herth, Philipp A. Schnabel, Hendrik Dienemann, Michael Meister
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
José Miguel Sánchez-Torres, Santiago Viteri, Miguel Angel Molina, Rafael Rosell
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Are three doses of SABR (stereotactic ablative radiotherapy) more effective than 30 doses of conventional radiotherapy?
Anna O. Simeonova, Katharina Fleckenstein, Hans-Jörg Wertz, Judit Boda-Heggemann, Frederik Wenz
Cetuximab in non-small-cell lung cancer
Robert Pirker, Martin Filipits
FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications
Hans-Ulrich Schildhaus, Lucia Nogova, Jürgen Wolf, Reinhard Buettner
MET inhibitors in combination with other therapies in non-small cell lung cancer
Sukhmani Padda, Joel W. Neal, Heather A. Wakelee
Adaptive resistance to targeted therapies in cancer
Rafael Rosell, Niki Karachaliou, Daniela Morales-Espinosa, Carlota Costa, Miguel Angel Molina, Irene Sansano, Amaya Gasco, Santiago Viteri, Bartomeu Massuti, Jia Wei, María González Cao, Alejandro Martínez Bueno
Inhibition of insulin-like growth factor receptor: end of a targeted therapy?
Rathi N. Pillai, Suresh S. Ramalingam

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song
Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

Original Article

BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper
The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

Review Article

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto, Fumihiro Tanaka
Prognostic markers in lung cancer: is it ready for prime time?
Chang-Qi Zhu, Ming-Sound Tsao
Potential biomarkers for lung cancer screening
Gabriella Sozzi, Mattia Boeri
Particle therapy in non-small cell lung cancer
Zhongxing Liao, Charles B. Simone II
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.


Original Article



Review Article





Erratum